Topically Applied IDP-118 Lotion and HP Monad Lotion in Subjects With Moderate to Severe Plaque Psoriasis

A Phase 1b Open-Label, Randomized Study Evaluating the Absorption and Systemic
Pharmacokinetics and HPA Axis Suppression Potential of Topically Applied IDP-118 Lotion and
HP Monad Lotion in Subjects with Moderate to Severe Plaque Psoriasis.

Inclusion Criteria:

- Male or Female of any race, at least 18 years old of age (inclusive)

- Freely provides both written and oral informed consent.

- Has a clinical diagnosis of psoriasis at the Baseline visit with an Investigator's
Global Assessment Score of 3 or 4. The face, scalp ,axillae, and intertriginous areas
are to be excluded in this calculation.

- Has an area of plaque psoriasis for topical treatment that involves a BSA of at least
20%.

- The willing and able to avoid prolonged exposure of the treatment area to ultraviolet
radiation (natural and artificial) for the duration of the study.

Key Exclusion Criteria:

- Has spontaneously improving or rapidly deteriorating plaque psoriasis or postural
psoriasis, as determined by the investigator.

- Presents with psoriasis that was treated with prescription medication and failed to
respond to presents).

- Has a history of adrenal disease.

- Presents with any other concurrent skin conditions that could interfere with the
evaluation of the treatment areas, as determined by the investigator.

- Is pregnant, nursing, or planning pregnancy during the study period.